Shares in 4d Pharma (LON:DDDD) are currently trading close to a 52 week high, with the share price up by around 24.1% to 144 over the past week. On a one-month basis, the 4d Pharma price has risen by 58.2%. For investors holding the st...
DDDD — 4d Pharma Share Price
0.000.00%
Last trade - 00:00HealthcareHighly SpeculativeSmall CapSucker Stock
- £76.90m
- £57.16m
- £0.53m
Momentum
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.94 | ||
| Price to Tang. Book | 2.97 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 156.94 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -175.99% | ||
| Return on Equity | -190.35% | ||
| Operating Margin | -14586.33% | ||
Financial Summary
| Year End 31st Dec | Unit | 2016 | 2017 | 2018 | 2019 | 2020 | 2021E | 2022E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | £m | n/a | n/a | n/a | 0.21 | 0.53 | n/a | 16.2 | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Health Trend(F-Score)
12345678910
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Latest News & Insights for DDDD
Shares in 4d Pharma (LON:DDDD) have led a strong move away from the market average in recent weeks. On a relative price strength basis, the price is up by 98.8% against the market over the past three months. The last close price was 98...
Shares in 4d Pharma (LON:DDDD) have outperformed the market over the past three months, signalling optimism on the part of investors at a time of economic uncertainty. Based on relative price strength against the market, the company's...
Profile Summary
4D pharma plc is a United Kingdom-based pharmaceutical company that focuses on developing Live Biotherapeutic Products (LBPs), which is a drug derived from the human microbiome. The Company's LBPs are biologics based on live organisms, namely single strains of bacteria. It has developed its research to build MicroRx, which is a discovery platform that is able to select those bacteria that have a therapeutic effect in specific diseases. It uses MicroRx to interrogate its library of bacterial isolates to identify LBPs. Its microbiome profiling platform, MicroDx, analyses the microbiome to aid the diagnosis and treatment of patients with its Live Biotherapeutics. Its MicroRx platform has generated a pipeline of development programs in therapeutic areas, including immuno-oncology, gastrointestinal (GI), respiratory, autoimmune and central nervous system (CNS) disease. It is conducting a phase I/II clinical study of MRx-4DP0004 in patients with poorly controlled asthma.
Directors
- Axel Glasmacher NEC (60)
- Duncan Peyton CEO (51)
- John Doyle CFO
- Alexander Stevenson CSO (50)
- Glenn Dourado OTH
- Edgardo Baracchini NID
- Sandy Macrae NID
- Paul Maier NID (73)
- Katrin Rupalla NID
- Last Annual
- December 31st, 2020
- Last Interim
- June 30th, 2021
- Incorporated
- January 10th, 2014
- Public Since
- February 18th, 2014
- No. of Employees
- 115
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- London Stock Exchange
- Shares in Issue
- 180,300,967
- Address
- 9 Bond Court, LEEDS, LS1 2JZ
- Web
- https://www.4dpharmaplc.com/
- Phone
- +44 1138950130
- Auditors
- RSM UK Audit LLP
Latest News for DDDD
Upcoming Events for DDDD
Full Year 2021 4D Pharma PLC Earnings Release
Similar to DDDD
4Basebio
London Stock Exchange
Allergy Therapeutics
London Stock Exchange
Arecor Therapeutics
London Stock Exchange
Avacta
London Stock Exchange
Bioventix
London Stock Exchange
FAQ
What is the 4d Pharma share price?
As of Today at 18:00 UTC, shares in 4d Pharma are trading at 42.65p. This share price information is delayed by 15 minutes.
How has the 4d Pharma share price performed this year?
Shares in 4d Pharma last closed at 42.65p and the price had moved by -63.7% over the past 365 days. In terms of relative price strength the 4d Pharma share price has underperformed the FTSE All Share Index by -67.85% over the past year.
What are the analyst and broker recommendations for 4d Pharma?
The overall consensus recommendation for 4d Pharma is Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the 4d Pharma dividend yield?
4d Pharma does not currently pay a dividend.
Does 4d Pharma pay a dividend?
4d Pharma does not currently pay a dividend.
When does 4d Pharma next pay dividends?
4d Pharma does not currently pay a dividend.
How do I buy 4d Pharma shares?
To buy shares in 4d Pharma you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of 4d Pharma?
As of the previous close price of 42.65p, shares in 4d Pharma had a market capitalisation of £76.90m.
Where are 4d Pharma shares listed?
Here are the trading details for 4d Pharma:
- Country of listing: United Kingdom
- Exchange: LSE
- Ticker Symbol: DDDD
What kind of share is 4d Pharma?
Based on an overall assessment of its quality, value and momentum 4d Pharma is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a 4d Pharma share price forecast for 2022?
The analyst consensus target price for shares in 4d Pharma is 360.00p. That is 744.08% above the last closing price of 42.65p.
Analysts covering 4d Pharma currently have a consensus Earnings Per Share (EPS) forecast of -£0.14 for the next financial year.
What is the trend in the 4d Pharma share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like 4d Pharma. Over the past six months, its share price has underperformed the FTSE All Share Index by -52.29%.
As of the last closing price of 42.65p, shares in 4d Pharma were trading -46.51% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the 4d Pharma PE Ratio?
The 4d Pharma PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at 42.65p.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of 4d Pharma?
4d Pharma's management team is headed by:
- Axel Glasmacher - NEC
- Duncan Peyton - CEO
- John Doyle - CFO
- Alexander Stevenson - CSO
- Glenn Dourado - OTH
- Edgardo Baracchini - NID
- Sandy Macrae - NID
- Paul Maier - NID
- Katrin Rupalla - NID